Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
NCT06103669
Recruiting
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma, Other Cancer
Register for Updates
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML
NCT06679582
Recruiting
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML... Read More
Gender:
ALL
Ages:
Between 1 day and 12 years
Trial Updated:
12/12/2024
Locations: Childrens Hospital of Alabama, Birmingham, Alabama +3 locations
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
Social Support and Enhanced Fear Extinction
NCT04565041
Recruiting
University of California, Los Angeles researchers will recruit healthy participants and anxious participants (those diagnosed with social anxiety disorder) age 18-55 years old to participate in a study examining whether the ability of social support figure reminders to enhance the extinction of fear in healthy participants extends to those with anxiety disorders. After being recruited from the UCLA community (healthy participants, n = 50) or referred by treatment providers at the Anxiety and De... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/12/2024
Locations: UCLA Department of Psychology, Los Angeles, California
Conditions: Fear, Anxiety
Register for Updates
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673
Recruiting
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Exelixis Clinical Site #1, Duarte, California +163 locations
Conditions: Non-Clear Cell Renal Cell Carcinoma
Register for Updates
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
NCT06191484
Recruiting
The purpose of the RISE study is to examine how the 24-hour rhythm of sleep and social activity relate to mood and suicidal ideation among older adults that recently lost a spouse or life partner.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/12/2024
Locations: University of Pittsburgh (UPMC), Pittsburgh, Pennsylvania
Conditions: Suicide, Bereavement
Register for Updates
Droperidol and QTc Interval Changes in ED Patients
NCT06726811
Recruiting
Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: CHRISTUS Spohn Hospital Corpus Christi-Shoreline, Corpus Christi, Texas
Conditions: Emergency Department Patient, QTc Intervals Changes
Register for Updates
Social Support and Reduced Fear Acquisition
NCT04564976
Recruiting
University of California, Los Angeles researchers will recruit healthy participants and anxious participants (those diagnosed with social anxiety disorder) age 18-55 years old to participate in a study examining whether the ability of social support figure reminders to prevent the acquisition of fear in healthy participants extends to those with anxiety disorders. After being recruited from the UCLA community (healthy participants, n = 50) or referred by treatment providers at the Anxiety and D... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/12/2024
Locations: UCLA Department of Psychology, Los Angeles, California
Conditions: Fear, Anxiety
Register for Updates
Contraception Navigator Program
NCT05691270
Recruiting
The goal of this study is to pilot test the IN-Control Birth Control Navigator Program in Central Indiana for use by adolescents who would like to access birth control. The investigators hypothesize that facilitating access to contraception through our intervention will ultimately result in increased feelings of autonomy around these decisions and use of hormonal contraception.
Gender:
FEMALE
Ages:
Between 15 years and 19 years
Trial Updated:
12/12/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Contraception, Contraceptive Usage, Health Care Utilization
Register for Updates
Baroreflex Activation Therapy in Left Ventricular Assist Device Patients Study
NCT06195046
Recruiting
This study will involve LVAD patients who have already received a clinically-indicated BAT (BAROSTIM) device. After recovery from LVAD implant, we will investigate the effects of BAT in a double-blind cross-over study design.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Congestive Heart Failure
Register for Updates
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
NCT06727396
Recruiting
This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/12/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Subjects
Register for Updates
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
NCT04752293
Recruiting
Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at A... Read More
Gender:
ALL
Ages:
Between 7 years and 18 years
Trial Updated:
12/12/2024
Locations: Wake Forest Health Sciences, Winston-Salem, North Carolina
Conditions: Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Register for Updates
Trial of PreoperAtive Radiation (TOPAz): a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation
NCT05774678
Recruiting
To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer removal and reconstruction).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates